METHOD FOR TREATING CANCER USING COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS Russian patent published in 2021 - IPC A61K31/506 A61K31/704 A61P35/00 

FIELD: medicine; pharmaceutics.

SUBSTANCE: invention relates to the field of medicine and pharmaceutics, namely, to a method for treating a proliferative disorder in a subject, which includes the administration of a DNA-damaging agent to the subject and the administration of a DNA-dependent protein kinase inhibitor (hereinafter – DNA-PK) to the subject during from 8 to 48 hours after the administration of the DNA-damaging agent, wherein the DNA-damaging agent is a doxorubicin agent; the proliferative disorder is a cancer selected from a group consisting of non-small cell lung cancer, small cell lung cancer, rectal and colon cancer, breast cancer, hepatic cell carcinoma, endometrial cancer and ovarian cancer; DNA-PK inhibitor is a compound selected from a compound B-1 or B-2, or its pharmaceutically acceptable salt, or a co-crystal containing the compound B-1 or its pharmaceutically acceptable salt or the compound B-2 or its pharmaceutically acceptable salt and a co-crystal formation selected from adipic, citric, fumaric, maleic, succinic and benzoic acid.

EFFECT: effectiveness of the administration of a DNA-PK inhibitor during from 8 to 48 hours after the administration of a DNA-damaging agent in the treatment of proliferative diseases.

33 cl, 29 dwg, 27 tbl, 10 ex